Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?

MeiraGTx Holdings PLC (MGTX) shares soared 6.2% in the last trading session to close at $8.09. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.8% gain over the past four weeks.

Last week, the company announced robust financial results for the fourth quarter and full- year 2025. Simultaneously, MeiraGTx announced that the FDA has granted a Breakthrough Therapy designation to AAV2-hAQP1 for the treatment of grade 2 and grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract. This might have driven the recent share price rally.

This company is expected to post quarterly loss of $0.62 per share in its upcoming report, which represents a year-over-year change of -21.6%. Revenues are expected to be $3.41 million, up 76.7% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For MeiraGTx, the consensus EPS estimate for the quarter has been revised 5.6% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on MGTX going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

MeiraGTx is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, CorMedix (CRMD), finished the last trading session 2.1% lower at $6.57. CRMD has returned -5.9% over the past month.

CorMedix's consensus EPS estimate for the upcoming report has changed -38.5% over the past month to $0.46. Compared to the company's year-ago EPS, this represents a change of +53.3%. CorMedix currently boasts a Zacks Rank of #4 (Sell).

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MeiraGTx Holdings PLC (MGTX): Free Stock Analysis Report

CorMedix Inc (CRMD): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research